Diabetes drug may lower death rate in obese people: study - The Hindu
GLP-1 agonists like semaglutide, originally for diabetes, show promise in weight loss and reducing cardiovascular mortality, heart attacks, and strokes in non-diabetic obese individuals. The SELECT trial found a 19% reduction in these events with semaglutide, but early death reduction and COVID-19 mortality effects raise questions. Baseline differences in loop diuretic use suggest more advanced heart disease in deceased participants, potentially skewing results.
Reference News
GLP-1 agonists like semaglutide, originally for diabetes, show promise in weight loss and reducing cardiovascular mortality, heart attacks, and strokes in non-diabetic obese individuals. The SELECT trial found a 19% reduction in these events with semaglutide, but early death reduction and COVID-19 mortality effects raise questions. Baseline differences in loop diuretic use suggest more advanced heart disease in deceased participants, potentially skewing results.